{"id":859570,"date":"2025-06-11T09:18:48","date_gmt":"2025-06-11T13:18:48","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-secures-biomarker-patent-for-novel-ptsd-therapeutic-spc-15-as-clinical-trial-nears\/"},"modified":"2025-06-11T09:18:48","modified_gmt":"2025-06-11T13:18:48","slug":"silo-pharma-secures-biomarker-patent-for-novel-ptsd-therapeutic-spc-15-as-clinical-trial-nears","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-secures-biomarker-patent-for-novel-ptsd-therapeutic-spc-15-as-clinical-trial-nears\/","title":{"rendered":"Silo Pharma Secures Biomarker Patent for Novel PTSD Therapeutic SPC-15 as Clinical Trial Nears"},"content":{"rendered":"<div class=\"mw_release\">\n<p>SARASOTA, FL, June  11, 2025  (GLOBE NEWSWIRE) &#8212; Silo Pharma, Inc. (Nasdaq: SILO) (\u201cSilo\u201d or the \u201cCompany\u201d), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced that the U.S. Patent and Trademark Office (USPTO) had issued a Notice of Allowance for U.S. Patent Application No. 17\/954,858 (titled \u201cBiomarkers for Efficacy of Prophylactic Treatments Against Stress-Induced Affective Disorders\u201d) that Silo licenses from Columbia University.\u00a0<\/p>\n<p>The to-be-issued patent will further strengthen Silo\u2019s IP protection for its lead asset, SPC-15, an intranasal treatment targeting post-traumatic stress disorder (PTSD). The patent is expected to issue as U.S. Patent No.\u00a012,329,726\u00a0on\u00a0June 17, 2025.<\/p>\n<p>Eric Weisblum, CEO of Silo, stated, \u201cThe original patent issued for this invention was filed by our collaborator Columbia University and supported by grants awarded by the National Institutes of Health (NIH). This patent offers increased protection for the key technology behind our novel PTSD prophylactic, which we are preparing to take into Phase 1 clinical trials.\u201d<\/p>\n<p>Silo holds an exclusive license agreement with Columbia University to further develop, manufacture, and commercialize SPC-15 globally. <\/p>\n<p>\n        <strong>About SPC-15<\/strong><br \/>\n        <br \/> SPC-15 is an intranasal serotonin 5-HT4 receptor agonist aimed at treating stress-induced psychiatric disorders such as PTSD and anxiety. With its potential eligibility for the FDA\u2019s streamlined 505(b)(2) regulatory pathway, SPC-15 offers a promising approach to accelerate the approval process. Silo Pharma is collaborating with Columbia University to conduct preclinical studies and has licensed exclusive rights to the development and commercialization of SPC-15 globally.<\/p>\n<p>\n        <strong>About Silo Pharma<\/strong><br \/>\n        <br \/> Silo Pharma Inc. (Nasdaq: SILO) is a developmental stage biopharmaceutical company focused on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company\u2019s portfolio includes innovative programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer\u2019s disease and multiple sclerosis. Silo\u2019s research is conducted in collaboration with leading universities and laboratories.\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=abl2hVn0Kth6h305io4o5TjdTmsNbT42skjLmtceCJ9hm5Kzr1F1ggwuvI8UaEWZSWaOOhwsyKTFo7J-b2tIZx_6BfpSM0dAGGtSRfY2T41ZvOqTyz1pgH9zjGtGNq1B5h4rtvei2Jh2wmY9HQj9i-yQOb2v5TVzbgc7q65AG1UuJZpJs4t18FiVdlxPxSGyxuwVvc2rkyVRsINIg_2Z-qNpQXtOzWPMKWdPeiCyHYg=\" rel=\"nofollow\" target=\"_blank\">silopharma.com<\/a><\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong><br \/>\n        <br \/> This news release contains &#8220;forward-looking statements&#8221; within the meaning of the \u201csafe harbor\u201d provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified using words \u201ccould\u201d, \u201cbelieve\u201d, \u201canticipate\u201d, \u201cintend\u201d, \u201cestimate\u201d, \u201cexpect\u201d, \u201cmay\u201d, \u201ccontinue\u201d, \u201cpredict\u201d, \u201cpotential\u201d, and similar expressions that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties, and other factors that could cause the actual results of Silo Pharma, Inc. (\u201cSilo\u201d or \u201cthe Company\u201d) to differ materially from the results expressed or implied by such statements, including changes to anticipated sources of revenues, future economic and competitive conditions, difficulties in developing the Company\u2019s technology platforms, retaining and expanding the Company\u2019s customer base, fluctuations in consumer spending on the Company\u2019s products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company disclaims any obligations to publicly update or release any revisions to the forward-looking information contained in this press release, whether as a result of new information, future events, or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events except as required by law.<\/p>\n<p>\n        <strong>Contact<\/strong>\n      <\/p>\n<p> 800-705-0120<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=H3NnAAF1NE5rWDjTul_aEmnsm-zVydZuku0g3NoIgx4nadb4ezjy3_EkbILrUJsFBiEBN8VUJop88dCPx17TJblw6MgDDffaL4UVFX0cU4W-jSF0mmXyR6qb8try8s4-QF_y0XosfPW7CoRPvdIV2VM_3zGBNow9AavJs_YHracxOydmta-yo5omCt4OQDeb53BFXkq3qdsaPjPIIj1Ial7boMqeimB7hThsP6JvE2js4MPF8GE7985rg_LjG1ZVxG5NuwxR2xkoWrsftPmbQHRa19UQlrs2jspRgtrco4uIPRsuKdnWSW2B0ACboD9fehqkXVWnxRVrcxiKSAjLsTu_KTJNKaTHeprD09iRLMRMqEurbiyySXb8o8sb7LT8Xi_gIT1-N4ZbyaM8kgxUjDh784WhIgPJEO75vdEFaX9dH5KxoeOEGr5QL073W8P570RdU8pum_Ooqpm07U4afJWKHHPEye2yrDkLCF3RGEqluy-qXpiYxjYYPNPvcm93WpLZ9ZK6eSAgla6vCqUG73lR4h8kF2FivOOayppnxtgUTxtdM5AFUBH7K1DipUAbC7XUemWazuh4ObrIwFnloUrTcVOmLj-nciIH4nq0a56FJPedlQhVnq9Ej5ZzAScNm9wG-ORgG4ITdLvBc2KfLqVNrPzZ89KmHrZLL3-FeDLfK9nIjLGxDXaA7afk2zA0iattTNHtkqwJd0Ftg1PTU1tzaCCbqVOmWb0ZqWZw7guQxhGyJ4aJ8KzXbZdf8oAJjwKHrFw_8r6T0Eeihyi1meZhNY8ZGjUXSULCkCYRvgc=\" rel=\"nofollow\" target=\"_blank\">investors@silopharma.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ2Njk0NCM2OTg2MTc4IzUwMDA2OTMzOQ==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MzUzMGRlMDItMTM2Ny00ZDQ1LTkxMzUtYjEyOTQzY2JkZTgzLTUwMDA2OTMzOS0yMDI1LTA2LTExLWVu\/tiny\/Silo-Pharma-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SARASOTA, FL, June 11, 2025 (GLOBE NEWSWIRE) &#8212; Silo Pharma, Inc. (Nasdaq: SILO) (\u201cSilo\u201d or the \u201cCompany\u201d), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced that the U.S. Patent and Trademark Office (USPTO) had issued a Notice of Allowance for U.S. Patent Application No. 17\/954,858 (titled \u201cBiomarkers for Efficacy of Prophylactic Treatments Against Stress-Induced Affective Disorders\u201d) that Silo licenses from Columbia University.\u00a0 The to-be-issued patent will further strengthen Silo\u2019s IP protection for its lead asset, SPC-15, an intranasal treatment targeting post-traumatic stress disorder (PTSD). The patent is expected to issue as U.S. Patent No.\u00a012,329,726\u00a0on\u00a0June 17, 2025. Eric Weisblum, CEO of Silo, stated, \u201cThe original patent issued for this invention was filed by our &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-secures-biomarker-patent-for-novel-ptsd-therapeutic-spc-15-as-clinical-trial-nears\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Silo Pharma Secures Biomarker Patent for Novel PTSD Therapeutic SPC-15 as Clinical Trial Nears&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-859570","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Silo Pharma Secures Biomarker Patent for Novel PTSD Therapeutic SPC-15 as Clinical Trial Nears - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-secures-biomarker-patent-for-novel-ptsd-therapeutic-spc-15-as-clinical-trial-nears\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Silo Pharma Secures Biomarker Patent for Novel PTSD Therapeutic SPC-15 as Clinical Trial Nears - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SARASOTA, FL, June 11, 2025 (GLOBE NEWSWIRE) &#8212; Silo Pharma, Inc. (Nasdaq: SILO) (\u201cSilo\u201d or the \u201cCompany\u201d), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced that the U.S. Patent and Trademark Office (USPTO) had issued a Notice of Allowance for U.S. Patent Application No. 17\/954,858 (titled \u201cBiomarkers for Efficacy of Prophylactic Treatments Against Stress-Induced Affective Disorders\u201d) that Silo licenses from Columbia University.\u00a0 The to-be-issued patent will further strengthen Silo\u2019s IP protection for its lead asset, SPC-15, an intranasal treatment targeting post-traumatic stress disorder (PTSD). The patent is expected to issue as U.S. Patent No.\u00a012,329,726\u00a0on\u00a0June 17, 2025. Eric Weisblum, CEO of Silo, stated, \u201cThe original patent issued for this invention was filed by our &hellip; Continue reading &quot;Silo Pharma Secures Biomarker Patent for Novel PTSD Therapeutic SPC-15 as Clinical Trial Nears&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-secures-biomarker-patent-for-novel-ptsd-therapeutic-spc-15-as-clinical-trial-nears\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-11T13:18:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ2Njk0NCM2OTg2MTc4IzUwMDA2OTMzOQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-secures-biomarker-patent-for-novel-ptsd-therapeutic-spc-15-as-clinical-trial-nears\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-secures-biomarker-patent-for-novel-ptsd-therapeutic-spc-15-as-clinical-trial-nears\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Silo Pharma Secures Biomarker Patent for Novel PTSD Therapeutic SPC-15 as Clinical Trial Nears\",\"datePublished\":\"2025-06-11T13:18:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-secures-biomarker-patent-for-novel-ptsd-therapeutic-spc-15-as-clinical-trial-nears\\\/\"},\"wordCount\":544,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-secures-biomarker-patent-for-novel-ptsd-therapeutic-spc-15-as-clinical-trial-nears\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ2Njk0NCM2OTg2MTc4IzUwMDA2OTMzOQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-secures-biomarker-patent-for-novel-ptsd-therapeutic-spc-15-as-clinical-trial-nears\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-secures-biomarker-patent-for-novel-ptsd-therapeutic-spc-15-as-clinical-trial-nears\\\/\",\"name\":\"Silo Pharma Secures Biomarker Patent for Novel PTSD Therapeutic SPC-15 as Clinical Trial Nears - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-secures-biomarker-patent-for-novel-ptsd-therapeutic-spc-15-as-clinical-trial-nears\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-secures-biomarker-patent-for-novel-ptsd-therapeutic-spc-15-as-clinical-trial-nears\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ2Njk0NCM2OTg2MTc4IzUwMDA2OTMzOQ==\",\"datePublished\":\"2025-06-11T13:18:48+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-secures-biomarker-patent-for-novel-ptsd-therapeutic-spc-15-as-clinical-trial-nears\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-secures-biomarker-patent-for-novel-ptsd-therapeutic-spc-15-as-clinical-trial-nears\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-secures-biomarker-patent-for-novel-ptsd-therapeutic-spc-15-as-clinical-trial-nears\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ2Njk0NCM2OTg2MTc4IzUwMDA2OTMzOQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ2Njk0NCM2OTg2MTc4IzUwMDA2OTMzOQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-secures-biomarker-patent-for-novel-ptsd-therapeutic-spc-15-as-clinical-trial-nears\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Silo Pharma Secures Biomarker Patent for Novel PTSD Therapeutic SPC-15 as Clinical Trial Nears\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Silo Pharma Secures Biomarker Patent for Novel PTSD Therapeutic SPC-15 as Clinical Trial Nears - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-secures-biomarker-patent-for-novel-ptsd-therapeutic-spc-15-as-clinical-trial-nears\/","og_locale":"en_US","og_type":"article","og_title":"Silo Pharma Secures Biomarker Patent for Novel PTSD Therapeutic SPC-15 as Clinical Trial Nears - Market Newsdesk","og_description":"SARASOTA, FL, June 11, 2025 (GLOBE NEWSWIRE) &#8212; Silo Pharma, Inc. (Nasdaq: SILO) (\u201cSilo\u201d or the \u201cCompany\u201d), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced that the U.S. Patent and Trademark Office (USPTO) had issued a Notice of Allowance for U.S. Patent Application No. 17\/954,858 (titled \u201cBiomarkers for Efficacy of Prophylactic Treatments Against Stress-Induced Affective Disorders\u201d) that Silo licenses from Columbia University.\u00a0 The to-be-issued patent will further strengthen Silo\u2019s IP protection for its lead asset, SPC-15, an intranasal treatment targeting post-traumatic stress disorder (PTSD). The patent is expected to issue as U.S. Patent No.\u00a012,329,726\u00a0on\u00a0June 17, 2025. Eric Weisblum, CEO of Silo, stated, \u201cThe original patent issued for this invention was filed by our &hellip; Continue reading \"Silo Pharma Secures Biomarker Patent for Novel PTSD Therapeutic SPC-15 as Clinical Trial Nears\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-secures-biomarker-patent-for-novel-ptsd-therapeutic-spc-15-as-clinical-trial-nears\/","og_site_name":"Market Newsdesk","article_published_time":"2025-06-11T13:18:48+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ2Njk0NCM2OTg2MTc4IzUwMDA2OTMzOQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-secures-biomarker-patent-for-novel-ptsd-therapeutic-spc-15-as-clinical-trial-nears\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-secures-biomarker-patent-for-novel-ptsd-therapeutic-spc-15-as-clinical-trial-nears\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Silo Pharma Secures Biomarker Patent for Novel PTSD Therapeutic SPC-15 as Clinical Trial Nears","datePublished":"2025-06-11T13:18:48+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-secures-biomarker-patent-for-novel-ptsd-therapeutic-spc-15-as-clinical-trial-nears\/"},"wordCount":544,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-secures-biomarker-patent-for-novel-ptsd-therapeutic-spc-15-as-clinical-trial-nears\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ2Njk0NCM2OTg2MTc4IzUwMDA2OTMzOQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-secures-biomarker-patent-for-novel-ptsd-therapeutic-spc-15-as-clinical-trial-nears\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-secures-biomarker-patent-for-novel-ptsd-therapeutic-spc-15-as-clinical-trial-nears\/","name":"Silo Pharma Secures Biomarker Patent for Novel PTSD Therapeutic SPC-15 as Clinical Trial Nears - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-secures-biomarker-patent-for-novel-ptsd-therapeutic-spc-15-as-clinical-trial-nears\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-secures-biomarker-patent-for-novel-ptsd-therapeutic-spc-15-as-clinical-trial-nears\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ2Njk0NCM2OTg2MTc4IzUwMDA2OTMzOQ==","datePublished":"2025-06-11T13:18:48+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-secures-biomarker-patent-for-novel-ptsd-therapeutic-spc-15-as-clinical-trial-nears\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-secures-biomarker-patent-for-novel-ptsd-therapeutic-spc-15-as-clinical-trial-nears\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-secures-biomarker-patent-for-novel-ptsd-therapeutic-spc-15-as-clinical-trial-nears\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ2Njk0NCM2OTg2MTc4IzUwMDA2OTMzOQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ2Njk0NCM2OTg2MTc4IzUwMDA2OTMzOQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-secures-biomarker-patent-for-novel-ptsd-therapeutic-spc-15-as-clinical-trial-nears\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Silo Pharma Secures Biomarker Patent for Novel PTSD Therapeutic SPC-15 as Clinical Trial Nears"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/859570","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=859570"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/859570\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=859570"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=859570"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=859570"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}